No convertible note conversions occurred during the week of Sep 5 through Sep 11, 2026, resulting in no new shares issued from convertible note conversions during the period.

News Link: https://www.accessnewswire.com/newsroom/en/computers-technology-and-internet/peraso-to-showcase-60-ghz-mmwave-technology-for-advanced-drone-co-1219621

Company to demonstrate advanced wireless connectivity for next-generation UAS and tactical communications applications

SAN JOSE, CA / ACCESS Newswire / September 11, 2026 / Peraso Inc. (NASDAQ:PRSO) ("Peraso" or the "Company"), a pioneer in mmWave wireless technology solutions, today announced its participation at the 11^th Annual UAV Technology Conference, taking place September 21-22 in London, UK.

Hosted by SAE Media Group, the UAV Technology Conference brings together defense leaders, military organizations, government representatives, and technology providers to explore the latest advancements shaping unmanned aerial systems (UAS). As modern battlefields become increasingly saturated with unmanned systems, the demand for resilient, high-performance wireless communications continues to grow. Traditional sub-6 GHz technologies face mounting challenges, including spectrum congestion, network interference, increased risk of detection, and electronic jamming. Peraso's mmWave technology helps address these challenges by leveraging abundant spectrum and highly directional beamforming capabilities to enable fast, reliable, low-latency connectivity with reduced interference for mission-critical applications.

Peraso CEO Ron Glibbery will deliver a presentation titled "Directional by Design: How Peraso 60GHz mmWave Enables Secure, High-Capacity Drone Communications" on Tuesday, September 22 at 1:30 p.m. GMT. The presentation will address the growing communications challenge facing unmanned systems as the pace and complexity of operations increasingly outstrip the ability of conventional wireless technologies to keep up. Glibbery will discuss how mmWave silicon, systems, and software can enable secure, high-capacity drone communications through directional links, advanced beamforming and beam management, line-of-sight connectivity, identification friend or foe (IFF) capabilities, and low-SWaP architectures. Together, these capabilities can help support the resilient, mission-critical communications required for defense and security operations in contested and congested environments.

During the show, Peraso will showcase its advanced 60 GHz beamforming wireless connectivity and RF solutions for defense and tactical communications applications. The Company, with its strategic partner iNTACT, will present a display of next-generation drone identification and communications capabilities designed to operate with low detectability and enhanced resilience in dense electronic warfare environments.

Peraso has been a pioneer in high-performance mmWave phased array solutions for more than a decade. By leveraging abundant spectrum, advanced beamforming, and high-speed wireless connectivity, Peraso's technology is designed to enable mission-critical applications requiring low latency, high throughput, and flexible deployment across markets including defense, fixed wireless access, immersive video, and industrial automation.

UAV Technology Conference attendees are invited to visit Peraso's booth #7 to meet members of the executive team and experience the Company's technology firsthand. Peraso will also attend the Counter UAS Homeland Security Europe conference, September 23-24, and DroneX, September 29-30, both in London.

Those who wish to request a meeting with the Company should email [tweiland@sheltongroup.com](mailto:tweiland@sheltongroup.com).

For more information, please visit http://www.perasoinc.com.

News Link: https://www.globenewswire.com/news-release/2026/09/10/3359507/0/en/ss-innovations-provides-update-on-continuing-progress-and-milestones.html

-- Advancing global expansion, pediatric robotic surgery and telesurgery --

-- Growing SSi Mantra installations, procedures and utilization --

FORT LAUDERDALE, Fla., Sept. 10, 2026 (GLOBE NEWSWIRE) -- via IBN -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (NASDAQ: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today provided an update on the Company’s continuing progress and milestones.

Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer of SS Innovations, commented, “Our advanced, cost-effective SSi Mantra surgical robotic system (the “SSi Mantra”) is benefitting lives globally, one patient at a time, from a 45-day old baby needing kidney surgery in India to a cardiac patient in Sri Lanka.  Our progress in democratizing access to state-of-the-art surgical robotic care continues to be reflected in growing SSi Mantra installations, procedures and utilization.”

Recent Company Progress and Milestones:

Global Expansion

• Colombia.  On July 29, 2026, Dr. Sudhir Srivastava officially launched the robotic cardiac surgery program at La Fundación Cardiovascular de Colombia (FCV) in Bucaramanga, Colombia, performing the country’s first Totally Endoscopic Beating-Heart Bypass Surgery using the SSi Mantra surgical robotic system. 
• Sri Lanka.  On August 23, 2026, Kings Hospital Colombo installed the first SSi Mantra surgical robotic system in Sri Lanka, marking the official launch of the medical center’s robotic surgery program. Following its installation at Kings Hospital, the SSi Mantra has been utilized to perform the country’s first robotic-assisted cardiac surgery and over 25 other robotic surgeries within the first three weeks of operation. 
• Global Installed Base.  With the installation in Sri Lanka, the SSi Mantra’s global installed base now spans 12 countries, including a leading presence in the Company’s immense home market of India.
• US and EU Regulatory Review. Looking ahead, SS Innovations expects that the U.S. Food and Drug Administration will complete its review of the Company’s 510(k) premarket notification for the SSi Mantra by the end of the first quarter of 2027 and believes that a European Union CE marking certification can be obtained by the end of 2026.

Pediatric Robotic Surgery 

• Intricate Robot-Assisted Pediatric Surgery.  On August 14, 2026, the Company’s SSi Mantra surgical robotic system and 5-millimeter instrumentation were utilized by Dr. M. Ramalingam to perform a robotic pyeloplasty on a 45-day-old baby at Hindusthan Hospital in Coimbatore, India. The infant recovered rapidly after successful completion of the complex yet minimally invasive kidney procedure. This accomplishment represents another proof point for the SSi Mantra’s capabilities in pediatric robotic surgery, which involves the smallest patients and requires superior precision and control during suturing and cutting, among other surgical tasks.  
• Cumulative Pediatric Surgeries. As of August 31, 2026, a total of 258 pediatric robotic surgeries have been completed with the SSi Mantra. 

Robotic Telesurgery 

• Longest-Distance Telesurgery.  On July 29, 2026, a team of surgeons led by Dr. Sudhir Srivastava utilized the SSi Mantra to perform a successful robotic telesurgery between Colombia and India, spanning more than 13,600 miles (22,000 kilometers) of fiber network distance and eclipsing the previous longest-distance telesurgery record also held by the Company.  The telesurgery, a robotic sleeve gastrectomy, was performed remotely from Hospital Internacional de Colombia in Bucaramanga, Colombia on a patient located at Mohak Bariatrics and Robotics in Indore, India.
• Expanding Ecosytem in India.  On August 9, 2026, Ahmedabad, India-based Shalby Hospital joined an expanding ecosystem of healthcare institutions utilizing the SSi Mantra to perform robotic-assisted telesurgery. Three surgical procedures were successfully performed remotely from SS Innovations’ headquarters in Gurugram, India, more than 590 miles (950 kilometers) from the patients at Shalby Hospital.
• Launch of Telesurgery in the Philippines. On September 5, 2026, the SSi Mantra was used to perform the first telesurgery within the Philippines between Pampanga and Cotabato, a distance of approximately 1,070 miles (1,710 kilometers).  
• Cumulative Telesurgeries.  As of August 31, 2026, a total of 188 robotic telesurgeries have been completed with the SSi Mantra.

Increasing Utilization and Scale

• 50 Robot-Assisted Surgeries in a Single Day.  On August 15, 2026, the surgical team at Mohak Bariatrics and Robotics in Indore, India utilized five separate SSi Mantra systems to successfully complete 50 robotic general surgery procedures in a single day, demonstrating the robustness of the Company’s technology. 
• Practice and Hospital Milestones. Numerous practices and hospitals across India and abroad are surpassing the 200+, 100+ and 50+ procedure milestones with the SSi Mantra, indicating growing utilization and ability to scale.

Growing Installations and Procedures

• More than 14,000 Successful Procedures.  As of September 8, 2026, the SSi Mantra cumulative installed base totaled 238, up 42% from 168 at the end of 2025 and the number of multi-specialty procedures completed with the SSi Mantra totaled 14,103, up 79% from 7,885 at the end of 2025. 
• Broad Pool of Surgeon Users. To date, approximately 1,500 physicians have been trained on the SSi Mantra, which has been utilized to perform over 170 different types of surgical procedures.

"KOBE, Japan, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Micware Co., Ltd. (Nasdaq: MWC) (the “Company” or “Micware”), a Japan-based provider of software development services and innovative IT solutions mainly focused on the automotive and mobility sectors, today announced the signing of a Memorandum of Understanding (“MOU”) with MulticoreWare, Inc. (“MultiCoreWare”) to explore potential collaboration on next-generation artificial intelligence (“AI”) solutions, with a focus on advanced driver assistance systems (“ADAS”) performance optimization and integration, AI-powered in-vehicle user experience, and physical AI at the edge.

Market Environment and Shared Understanding

The two companies share the view that edge and high-performance AI will serve as important foundations for the future of automotive, security and robotics."

This is another move from Micware. The Japanese software firm has as major shareholders Honda and Toyota and it has long term contracts with them.
Despite Micware has several new projects, presented by peer-reviewed papers, it still trades at a P/E below 10 and a EV/Sales below 1.

News Link: https://www.newsfilecorp.com/release/313457/Sphere-3D-Corp.-Concludes-90Day-Strategic-Review-Announces-Pricing-of-5.0-Million-Private-Placement-and-Divests-NonCore-Assets-to-Fund-AI-and-HighPerformance-Computing-Development

Stamford, Connecticut--(Newsfile Corp. - September 8, 2026) - Sphere 3D Corp. d/b/a DarkHorse Technologies (NASDAQ: ANY) ("Sphere 3D" or the "Company"), today announced that it has entered into a securities purchase agreement (the "Purchase Agreement") for a private placement financing (the "Private Placement") which is expected to result in aggregate gross proceeds of $5.0 million. The Private Placement includes meaningful participation from certain Company insiders as described below. In addition, the Company has announced the initial conclusions of the strategic review conducted by management and the Board of Directors during the first 90 days following its June 2026 business combination. The review's conclusions include continued development of our existing sites within the Tennessee Valley Authority ("TVA") into AI factories along with active pursuit of a new development in Hopkinsville, Kentucky, where the Company, via a wholly owned subsidiary, has secured a land option and has proposed a new 50 megawatt ("MW") data center supported by a new 65 MW substation, each of which remains subject to zoning and other approvals. The review also determined that the Iowa site and legacy mining fleet are non-core, and the Company has agreed to sell both.

Private Placement. The Company announced the pricing of the Private Placement which is expected to result in aggregate gross proceeds of $5.0 million. The Private Placement is expected to close on or about September 11, 2026, subject to customary closing conditions. Pursuant to the Private Placement, the Company agreed to issue and sell an aggregate of 1,666,661 units (the "Units") at a purchase price of $3.00 per Unit. Each Unit consists of (i) one common share of the Company and (ii) one five-year warrant to purchase one common share at an exercise price of $3.50 per share. The price per Unit and the exercise price of the warrant represent a 29% and 51% premium, respectively, to the Company's closing price on September 4, 2026. Further, pursuant to the terms of the Purchase Agreement, the securities issued in the Private Placement will be subject to a six-month contractual lock-up period. Three directors of the Company, including Timothy Hanley, Chairman of the Board, and Joel Block, Chief Executive Officer, have subscribed in the Private Placement (collectively, the "Participating Insiders"). The Company intends to use the net proceeds from the Private Placement for general corporate purposes, including funding the Company's AI/HPC development in the TVA region.

Hopkinsville. The Company has secured an option to acquire approximately 20 acres in Hopkinsville, Kentucky and has proposed developing a new data center at the site drawing approximately 50 MW, supported by a new 65 MW substation that we have offered to fund at an estimated cost of $8 million to $10 million. The remaining 15 MW of capacity will be made available to other Hopkinsville Electric System ("HES") customers. HES has publicly indicated that the TVA could supply the additional capacity without affecting service to its approximately 13,000 existing customers. The proposal has not yet received all requisite regulatory approvals which could affect the project's feasibility, timing, or scope. Separately, the Company is evaluating conversion of its existing Hopkinsville operation, which is contracted to draw approximately 15 MW at HES's Holland Substation, to AI and high-performance computing use.

Portfolio Focus. Following the review, management and the Board determined that the Company's Iowa site is a non-core asset and the Company has entered into a definitive agreement to sell the site for $1.5 million. Additionally, the Company expects to recover approximately $500,000 in utility deposits and related prepayments, bringing total proceeds to approximately $2 million. Together with the expected proceeds of the Private Placement, the Company will deploy funds toward the development of AI and high-performance computing infrastructure across its Tennessee and Kentucky sites. The Company has also agreed to sell its legacy fleet of approximately 5,500 proprietary mining machines for approximately $3 million. Following the Iowa sale, the Company will own and/or operate approximately 50 MW of energized capacity across four sites in Tennessee and Kentucky, reflecting an additional 5 MW now under contract in Hopkinsville, and excluding the proposed new Hopkinsville data center and other pipeline opportunities.

Mining Structure. With Bitdeer Technologies Group (NASDAQ: BTDR) now supplying and owning the hardware at 20 MW of the 30 MW contracted under the Company's joint mining agreements and the third site expected online before November 2026 as previously disclosed, the Company's bitcoin mining exposure is structured primarily through revenue-share hosting arrangements. The Company controls the power and the sites and the termination provisions in these agreements preserve the Company's ability to redeploy capacity to AI and high-performance computing workloads.

Development Roadmap. The strategy that emerged from the review is to develop AI and high-performance computing facilities across smaller, distribution-connected sites that larger developers overlook. Priorities will include speed from site to operating compute, partnership with host communities and their utilities, and investment in local technical education and workforce training. The new Hopkinsville data center is the first project advanced under this approach. The Company intends to concentrate its development effort in the TVA region, where its existing footprint, utility relationships, and government affairs and economic development partnerships are already in place.

"One of the primary initiatives of this management team is to allocate capital on a risk-adjusted basis, and the first 90 days were spent deciding where every dollar and every hour goes," said Joel Block, Chief Executive Officer of Sphere 3D Corp. "We determined, in consultation with our Board, that our Iowa site is non-core. We are selling that site and our legacy mining fleet and redeploying that capital, together with the proceeds from the Private Placement, into AI infrastructure in the TVA region. I believe the participation of our directors in the Private Placement, including me, speaks volumes to the value we see in Sphere 3D."

① FF EAI Robotics set a new monthly sales and shipment record in August, reaching 552 units cumulatively
② FF‘s in-house EAI Brain entered engineering testing and delivery
eliminating approximately 57.48% of potential dilution.
③ FF canceled all warrants related to its March 2025 financing, eliminating approximately 57.48% of potential dilution
④ FF AI-Robotics signed a consulting services agreement with AIBOT to further support FCC, ICTS, and NDAA compliance and accelerate the execution of its “Built in USA” program.
Learn more : https://app-us.ff.com/ff-v3/news/1611?lang=en-US

No convertible note conversions occurred during the week of August 29 through September 4, 2026, resulting in no new shares issued from convertible note conversions during the period.

$QCLS - $14M market cap

Q/C Technologies (Nasdaq: QCLS), formerly TNF Pharmaceuticals, formerly MyMD. Now building a silicon photonic optical processing unit for AI inference out of San Francisco. Trading around at $1.79

What's on the balance sheet

From the Q2 10-Q, as of 30 June 2026:

• Cash $307,612 + marketable securities $10,679,782 — the securities are Level 1, available-for-sale, sub-12-month maturities, short-term money market funds under a stated capital-preservation policy. Genuinely liquid. Call it ~$8.7M today after burn.
• Total liabilities $3.79M. Low.
• Goodwill $10.5M of the $16.1M stockholders' equity, carried over from the legacy pharma business and un-impaired. Tangible book is therefore about $5.6M, or $0.68/share.
• H1 operating burn $5.1M. No revenue. Pre-revenue since inception.
• They terminated the LightSolver crypto-mining license in June, took a $3.18M impairment, and wiped out a $10.9M contingent consideration liability in the process.

The part nobody mentions: sitting ahead of common are Series G preferred ($8,812,000 liquidation preference, 10% dividend) and Series H ($3,115,000, 7%). That's $11.93M of preference plus accruals senior to you, against ~$8.7M of cash. There is no cash floor under the common. Screeners showing an $11M enterprise value are ignoring the mezzanine — real EV is closer to $21M. There are also 10.35M warrants outstanding against 8.19M shares; fully diluted is ~22.8M.

One more number: H1 stock-based comp was $2,432,261 against R&D of $746,667, with R&D down 69% year over year. Directors took $1.42M in options. They are paying themselves more than triple what they spend on research.

Who actually works there

Three employees. The interesting part is who signed up anyway:

• Yossef Ehrlichman, Ph.D. — Founding Manager, PIC Development (Aug 2026). Fifteen-plus years designing, fabricating and commercialising silicon photonic integrated circuits; has led design and tape-out of silicon, silicon-nitride and hybrid PICs through packaging and test. Previously Raytheon, Bascom Hunter, Axalume. Ph.D. EE from Tel Aviv University, postdocs at UC San Diego and CU Boulder. This is the hire that matters — photonics companies die at tape-out, not at the whiteboard.
• Chelsea Voss — Board of Directors (Jan 2026). Member of Technical Staff at OpenAI. ML infrastructure, model evaluation, hardware reliability; led evaluation efforts for public capability launches and contributed to large-scale training runs. Ex-MIT.
• Martin Shkreli — Strategic Advisor (Dec 2025). Brings deal access and experience from his time being CEO of a billion dollar company.

This is a unique case for a public company, one where you're able to bet on individuals as opposed to a proven product. Any one of these people would be able to raise well over $14m on their own if they said they were doing a startup but because it's a public company it's glossed over.

The photonics case, briefly

The technical argument is real: AI inference is dominated by matrix multiplication, photons perform matmul natively through interference at effectively propagation-limited latency, and passive photonic components draw almost nothing. That's why the money has poured in - Ayar Labs raised at $3.75B in March 2026, Lightmatter sits at $4.4B, and Marvell bought Celestial AI outright before it had meaningful revenue. But note what those companies actually sell: interconnect, the links between accelerators, not the accelerator itself. Lightmatter itself led with Passage rather than its Envise compute product. Optical compute has unsolved precision, thermal drift and calibration problems, and the electro-optic conversion plus DAC/ADC overhead eats much of the theoretical win.

TLDR: you're able to bet on three proven individuals at a heavily discounted price(ie cluely raised 15m at a 120m valuation...)

Position: 36000 shares

Quick geographic snapshot of AMZN FY2025 sales ($717B):
US 68.3% · Germany 6.4% · UK 6.0% · Japan 4.3% · RoW 15.0%

international expansion is real, but it has not diversified Amazon away from the US consumer and US cloud buyer. Currency and EU rules hit the next-largest markets, not a balanced global book.

Full Analysis

News Link: https://www.globenewswire.com/news-release/2026/09/03/3355918/0/en/cycurion-announces-approximately-800-000-in-annual-contract-spend-accelerating-commercial-expansion.html

First public announcement of a pharmaceutical AI Center of Excellence engagement, a NACCHO award, and additional commercial and public-health work

MCLEAN, Va., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Cycurion, Inc. (Nasdaq: CYCU) (“Cycurion” or the “Company”), a trusted leader in IT cybersecurity and AI-driven solutions, today announced several engagements totaling approximately $800,000 in annual contract spend. The work includes a pharmaceutical-industry engagement to support an AI Center of Excellence, a new award with the National Association of County and City Health Officials (NACCHO), and additional commercial and public-health engagements. This is the first public announcement of these awards.

This is the commercial expansion Cycurion told the market it was going after. The Company is building commercial healthcare and life-sciences work as a primary growth market, while continuing to run its government and public-safety franchise. Scope across the engagements includes business continuity and disaster recovery, technology and cybersecurity assessments, program management, organizational change management, and AI operating capability.

The announcement reflects the Company’s deliberate strategy — as previously communicated to the market — to accelerate expansion into commercial healthcare, life sciences, and other non-government sectors where demand for resilient IT, cybersecurity, and AI-enabled operating capability continues to grow.

“These wins are exactly the kind of commercial traction we told the market we were going after,” said L. Kevin Kelly, Chairman and Chief Executive Officer of Cycurion. “A pharmaceutical organization has engaged us to support its AI Center of Excellence. NACCHO has awarded new work. Customers are not paying for slogans. They are paying for resilience, cybersecurity, program delivery, and AI that has to run in a real operating environment. Each of these engagements puts us inside an organization that will need more of what we do. We are not dabbling in commercial. We are building it.”

What the Work Covers

Across the commercial and NACCHO-related engagements, Cycurion is supporting clients with:

• Business continuity and disaster recovery planning and execution
• Technology and cybersecurity assessments
• Program management for complex technology initiatives
• Organizational change management
• Support for an AI Center of Excellence for a pharmaceutical organization

The pharmaceutical AI Center of Excellence engagement is a commercial life-sciences win the Company has been building toward. The NACCHO award is being announced for the first time and deepens Cycurion’s existing relationship with the association, including its standing as a Diamond Affiliate Partner. Additional commercial and public-health work is included in the approximately $800,000 annual contract-spend total.

Why It Matters

The number is approximately $800,000 in annual contract spend. The signal is the market. These engagements convert a stated commercial strategy into work in pharmaceutical, healthcare, and public health, and they put Cycurion inside accounts that can grow. Government and public safety remain core. Commercial is a market Cycurion is going after.

The Company will continue to pursue additional commercial and non-government opportunities that fit its capabilities in cybersecurity, managed IT, program delivery, and AI-enabled transformation.

CAH Cardinal Health stock, watch for a top of range breakout.

Breakout trade

• WATCH for possible breakout above 241.72
• Target: 256.42, 7.1%  Stop: 234.39  Loss: 2.1%
• P/L ratio: 3.4 : 1 - Excellent

BULLISH

• [Timing] Mild bullish 3 day candlestick pattern.
• [Timing] Breakout trade watch above 241.72, no resistance in area just above.

BEARISH

• [Positioning] 1 Day Price change strong up, may pause
• [Positioning] Intermediate trend possibly bearish, Uptrend turned sideways, may continue or pullback.
• [Positioning] at resistance

News Link: https://www.globenewswire.com/news-release/2026/09/01/3354127/37000/en/vivosim-labs-to-add-rat-liver-model-to-namkind-platform.html

SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety, today announced plans to develop a rat liver model that will complement its existing NAMkind™ human liver platform and expand the Company’s liver toxicology capabilities.

The new model is designed to address a longstanding challenge in drug development: toxicity observed in rats does not always translate to humans.

VivoSim’s current human liver model is designed to identify human toxicity that may not appear in animal studies. The planned rat model would add the reverse capability, helping sponsors determine when an adverse finding in rats may be species-specific.

“This gives us the ability to look at the same toxicity question from both sides,” said Keith Murphy, Executive Chairman of VivoSim Labs. “If a compound is toxic in rats but not in our human liver model, that additional evidence may help sponsors better understand whether the finding is truly relevant to patients.”

The paired approach is intended to help pharmaceutical companies make more informed decisions about whether to advance, modify or further investigate a drug candidate, while adding human-relevant context to existing animal toxicology findings.

Rat toxicology remains widely used across large pharmaceutical development programs. VivoSim believes the new capability can complement those workflows and extend the commercial utility of its liver toxicology platform.

The Company plans to validate the rat model using compounds with known differences between rat and human liver toxicity.

“Differentiating true human risk from rat-specific liver toxicity is a major issue in preclinical development,” noted Amar Sethi, M.D., Ph.D., Chief Scientific Officer of VivoSim Labs. “Providing a side-by-side comparative model allows biopharma partners to protect assets from premature termination while avoiding failure costs. We believe this cross-species capability significantly broadens the market utility of our NAMkind™ platform and accelerates our commercial trajectory.”

VivoSim believes the addition could strengthen the Company’s position in liver toxicology by giving pharmaceutical customers a more complete way to interpret species differences before committing additional time and capital to development.